Study Of The Treatment Of Anti-Osteopontin Antibody On Type Ⅱ Collagen Induced Arthritis In Rats And Its Effect On The Synovial Proliferation And Angiogenesis

Objiective: To inverstigate anti-osteopontin antibody on the treatment of limbs inflammation,synovium hyperplasia and angiogenesis in collagen induced arthritis rat(CIA). To explore the mechanisms of the anti-osteopontin antibody in the treatment of rheumatoid arthritis.Methods: The rats were devides into 3 groups randomly: the untreated group, the group treated with physiological saline, the group treated with anti-osteopontin antibody. Physiological saline group and anti-osteopontin antibody group were collagen induced arthritis rats. Bovine Câ…¡was emulsified in Freud's incomplete adjuvant. The model were injected intradermally at the base of the tail. Arthritis were evaluated by arthritis index. The third foot pad of forelimb were stained by HE dyeing, whilst neutrophil, lymphocyte and plasmacyte infiltration, hyperplasia of synovium and hyperplasia of fibrous tissue were assessed by histopathological index. Immunohistochemistry method was adopted to detect the PECAM-1(CD31) of the synovium. Effect of anti-osteopontin antibody on CIA were observed.Result The arthritis indexs of physiological saline group and anti-osteopontin antibody group were increased with time, the AI of anti-osteopontin antibody group were lower than those of physiological saline group. The were infiltration of neutrophils, lymphocytes, plasmacytes, hyperplasia of synoviocytes, hyperplasia of fibrous tissue and cartilage destrucition in pathology. The histopathological scores of anti-osteopontin group were lower than those of physiological saline group. Anti-osteopontin antibody could inhibit hyperplasia of synoviocytes(P<0.05). The levels of PECAM-1(CD31) of the model group were notably higher than those of anti-osteopontin antibody group(P<0.05).Conclusion Anti-osteopontin antibody can notably relieve the arthritis syndrome and retard the cartilage damage of CIA in rats, and could significantly decrease the PECAM-1(CD31) in the synovium. Which may be one of the therapeutic mechanism. This study provides an experimental evidence for anti-osteopontin antibody in treating rheumatoid arthritis.